文献速递骨软组织肉瘤与黑色素瘤

四肢或躯干高级别骨肉瘤的预后因素:对1702例接受新辅助协作骨肉瘤研究组方案治疗患者的分析

Prognostic Factors in High-Grade Osteosarcoma of theExtremities or Trunk: An Analysis of 1,702 Patients Treatedon Neoadjuvant Cooperative Osteosarcoma Study GroupProtocols.
PubMed 文献 · J Clin Oncol · 2023-01-01

该分析纳入1998年7月前登记于协作骨肉瘤研究组新辅助研究的1702例 consecutive 新诊断躯干或肢体高级别骨肉瘤患者,评估人口学、肿瘤及治疗相关变量与缓解和生存的关系。中轴部位、男性和症状史长与化疗反应差相关;10年总生存率和无事件生存率分别为59.8%和48.9%。诊断时可评估的年龄、肿瘤部位、原发转移以及肢体骨肉瘤的大小和部位显著影响结局,化疗反应和手术范围也是重要预后因素;多因素分析中除年龄外均保持显著性,手术缓解和组织学反应是关键预后因素。

要点

  • 中轴肿瘤部位、男性和症状史长与化疗反应差相关。
  • 10年总生存率和无事件生存率分别为59.8%和48.9%。
  • 多因素分析中手术缓解和组织学反应是关键预后因素。

核心结论

  • 肿瘤部位和大小、原发转移、化疗反应和手术缓解在骨肉瘤中具有独立预后价值。

研究设计与样本

  • 分析1998年7月前登记于协作骨肉瘤研究组新辅助研究的1702例 consecutive 新诊断躯干或肢体高级别骨肉瘤患者。
  • 分析人口学、肿瘤相关和治疗相关变量、缓解和生存。
  • 预定治疗策略包括术前和术后多药化疗以及所有可手术病灶的手术。

主要发现

  • 中轴肿瘤部位、男性和症状史长在单因素和多因素分析中与化疗反应差相关。
  • 10年总生存率和无事件生存率分别为59.8%和48.9%。
  • 诊断时可评估变量中,年龄≥40岁10年生存率41.6% vs <40岁60.2%(P = .012),中轴部位29.2% vs 肢体61.7%(P < .0001),原发转移有26.7% vs 无64.4%(P < .0001)。
  • 肢体骨肉瘤中,大小≥三分之一52.5% vs <三分之一66.7%(P < .0001),肢体近端部位49.3% vs 其他63.9%(P < .0001)。
  • 化疗反应差47.2% vs 好73.4%(P < .0001),手术不完全14.6% vs 肉眼完全64.8%(P < .0001)。

关键数值与推荐

  • 年龄≥40岁10年生存率41.6% vs <40岁60.2%(P = .012)。
  • 中轴部位10年生存率29.2% vs 肢体61.7%(P < .0001)。
  • 原发转移有10年生存率26.7% vs 无64.4%(P < .0001)。
  • 肢体骨肉瘤大小≥三分之一10年生存率52.5% vs <三分之一66.7%(P < .0001)。
  • 肢体骨肉瘤近端部位10年生存率49.3% vs 其他63.9%(P < .0001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To define prognostic factors for response and long-term outcome for a wide spectrum of osteosarcomas, extending well beyond those of the typical young patient with seemingly localized extremity disease. PATIENTS AND METHODS: A total of 1,702 consecutive newly diagnosed patients with high-grade osteosarcoma of the trunk or limbs registered into the neoadjuvant studies of the Cooperative Osteosarcoma Study Group before July 1998 were entered into an analysis of demographic, tumor-related, and treatment-related variables, response, and survival. The intended therapeutic strategy included preoperative and postoperative chemotherapy with multiple agents as well as surgery of all operable lesions. RESULTS: Axial tumor site, male sex, and a long history of symptoms were associated with poor response to chemotherapy in univariate and multivariate analysis. Actuarial 10-year overall and event-free survival rates were 59.8% and 48.9%. Among the variables assessable at diagnosis, patient age (actuarial 10-year survival ≥ 40, 41.6%; < 40, 60.2%; P = .012), tumor site (axial, 29.2%; limb, 61.7%; P < .0001), and primary metastases (yes, 26.7%; no, 64.4%; P < .0001), and for extremity osteosarcomas, also size (≥ one third, 52.5%; < one third, 66.7%; P < .0001) and location within the limb (proximal, 49.3%; other, 63.9%; P < .0001), had significant influence on outcome. Two additional important prognostic factors were treatment related: response to chemotherapy (poor, 47.2%; good, 73.4%; P < .0001) and the extent of surgery (incomplete, 14.6%; macroscopically complete, 64.8%; P < .0001). All factors except age maintained their significance in multivariate testing, with surgical remission and histologic response emerging as the key prognostic factors. CONCLUSION: Tumor site and size, primary metastases, response to chemotherapy, and surgical remission are of independent prognostic value in osteosarcoma.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic Factors in High-Grade Osteosarcoma of theExtremities or Trunk: An Analysis of 1,702 Patients Treatedon Neoadjuvant Cooperative Osteosarcoma Study GroupProtocols. J Clin Oncol. 2023. PMID: 37713812. doi:10.1200/JCO.22.02767

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。